Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?-A Systematic Review.
Tim A C de VriesJack HirshKe XuImaad MallickVinai C BhagirathJohn W EikelboomJeffrey S GinsbergPaul C KrugerNoel C ChanPublished in: Thrombosis and haemostasis (2020)
The higher risk profiles of patients in OSs versus RCTs, and higher rates of both bleeding and mortality not attributable to thromboembolism in patients treated with apixaban 2.5 versus 5 mg twice daily suggest that differences in patient characteristics are additional important contributors to the higher than expected thromboembolic event rates in clinical practice.
Keyphrases
- atrial fibrillation
- clinical practice
- oral anticoagulants
- left atrial
- catheter ablation
- end stage renal disease
- direct oral anticoagulants
- left atrial appendage
- heart failure
- ejection fraction
- venous thromboembolism
- newly diagnosed
- chronic kidney disease
- percutaneous coronary intervention
- peritoneal dialysis
- prognostic factors
- coronary artery disease
- type diabetes
- mitral valve